In a clinical study, KRAS/NRAS mutations were identified in 316 (42.6%) CRC patients, and BRAF mutations were identified in 47 (7.2%) CRC patients (Yurgelun et al., 2017). This evidence concerns the gene KRAS and colorectal carcinoma.